PhRMA Defends Sustainability and Waste Management Practices

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The Pharmaceutical Research and Manufacturers of America released a statement this week in response to recent media reports regarding the amount of pharmaceutical ingredients being discharged by manufacturing facilities into the environment.

The Pharmaceutical Research and Manufacturers of America released a statement this week in response to recent media reports regarding the amount of pharmaceutical ingredients being discharged by manufacturing facilities into the environment. In the statement, PhRMA insists that “American pharmaceutical companies comply with environmental regulations as part of their New Drug Applications and manufacturing processes.” The process reportedly includes environmental impact evaluations and “extensive” data analysis.

The organization argues that an Associated Press story claiming drugmakers have released more than 271 million pounds of compounds into waterways, including those providing drinking water, is misleading and fails to mention key information. Responding to the AP story’s claim that the majority of the these compounds are pharmaceutical ingredients, PhRMA insists “the two most prominent substances mentioned in [the story] are primarily industrial chemicals, and their use as pharmaceutical is miniscule by comparison.” These two substances are hydrogen peroxide and phenol, which, according to PhRMA makes up 92% of the alleged 271 million pounds.

The statement also points out that the AP story fails to note the absence of health effects associated with the trace levels detected. “Only trace amounts of pharmaceuticals are found in the environment, and scientific studies conducted to date have not indicated any appreciable risk to human health.” Meanwhile, individual pharmaceutical companies are also posting statements about their environmental impact practices, including Novo Nordisk and Astra Zeneca.

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes